Boothbay Fund Management’s Silence Therapeutics SLN Stock Holding History

Boothbay Fund Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Sell	198,347 -10,741	-5%	-$75.6K	0.03%	691
2026 Q1	$1.1M	Hold	209,088	–	–	0.01%	897
2025 Q4	$1.27M	Sell	209,088 -70,549	-25%	-$452K	0.02%	708
2025 Q3	$1.45M	Buy	279,637 +27,216	+11%	+$151K	0.02%	680
2025 Q2	$1.46M	Buy	252,421 +2,409	+1%	+$10.3K	0.03%	572
2025 Q1	$705K	Sell	250,012 -101,515	-29%	-$496K	0.02%	739
2024 Q4	$2.42M	Buy	351,527 +180,372	+105%	+$2.33M	0.06%	394
2024 Q3	$3.11M	Buy	171,155 +24,303	+17%	+$452K	0.07%	383
2024 Q2	$2.79M	Buy	146,852 +19,628	+15%	+$417K	0.07%	401
2024 Q1	$2.75M	Buy	+127,224	New	+$2.77M	0.05%	402

Other funds holding SLN

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Boothbay Fund Management's SLN Position: Q2 2026 in Review

Boothbay Fund Management reduced its Silence Therapeutics (SLN) stake by 5.1% in Q2 2026, selling an estimated $75.6K and leaving 198,347 shares worth $2.18M. The position accounts for 0.03% of the portfolio, ranked #691.

Boothbay Fund Management first reported a position in SLN in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.11M in Q3 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

Boothbay Fund Management held 198,347 shares of Silence Therapeutics worth $2.18M as of Q2 2026.
Boothbay Fund Management sold 10,741 Silence Therapeutics shares in Q2 2026, an estimated $75.6K.
Silence Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #691 holding.
Boothbay Fund Management first reported a position in Silence Therapeutics in Q1 2024 and has held it in 10 quarters since.
Boothbay Fund Management's Silence Therapeutics position peaked at $3.11M in Q3 2024.
72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.